Several signalling pathways were found to be modified by PCDH10 expression or re-expression: increased pro-apoptotic NFκB signalling in multiple myeloma [36], decreased β-catenin/Wnt signalling in endometroid endometrial cancer cell lines, multiple myeloma, lymphoma and colorectal carcinoma cells [35, 37, 42, 45], and inhibition of the PI3K/Akt signalling pathway in hepatocellular and colorectal carcinoma cells [43, 45]. This evidence concerns the gene PCDH10 and plasma cell myeloma.